Xcout IntelSign inSubscribe

DIASORIN

0GZXBiotechItaly

Diasorin S.p.A. is an Italian multinational biotechnology company that produces and markets in vitro diagnostics reagent kits used in immunodiagnostics and molecular diagnostics and since July 2021, it is also active in the Life Science business. The group was founded in 2000 and is headquartered in Saluggia, Italy. Its production is at several plants located in Europe and the United States: Saluggia and Gerenzano (Italy), Dietzenbach (Germany), Stillwater, Minnesota (US), Dartford (UK). Following the acquisition of Luminex, the company acquired five additional production plants located in th

Subscribe to see DIASORIN’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

DIASORIN at a glance

DIASORIN is a biotech company headquartered in Italy. Xcout tracks 2 named people at DIASORIN, including Gustavo Denegri (Owner).

Industry
Biotech
Headquarters
Italy
Ticker
0GZX

DIASORIN leadership

  • Gustavo DenegriOwner
  • Gustavo DenegriChairman

DIASORIN competitors

A few of DIASORIN's closest competitors — see the full list of competitors and alternatives →

TRINITY BIOTECH PLCTRIB · BiotechBray, Ireland
66% matchPublic

Trinity Biotech plc, an Irish enterprise founded in 1992 and headquartered in Bray, is engaged in the acquisition, development, manufacturing, and global distribution of medical diagnostic solutions. The company's reach extends to the Americas, Africa, Asia, and Europe, catering to both clinical laboratory and point-of-care diagnostic markets. Its extensive range of clinical laboratory offerings encompasses diagnostic tests and specialized instrumentation for identifying numerous infectious diseases. These include Lyme disease, sexually transmitted infections like syphilis and herpes, SARS-CoV-2, and a variety of viral pathogens such as Epstein Barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, and varicella. Additionally, Trinity Biotech provides in-vitro diagnostic products centered on haemoglobin A1c for the crucial monitoring, diagnosis, and risk assessment of diabetes. The company's product development incorporates diverse assay formats, including immunofluorescence, enzyme-linked immunosorbent (ELISA), Western blot, and line immunoassays. It also supplies a suite of reagent products, including ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase, vital for diagnosing liver and kidney disorders, as well as haemolytic anaemia. Beyond diagnostics, Trinity Biotech serves the life sciences industry and research facilities by supplying raw materials. The company's customer base comprises public health authorities, non-governmental organizations, and both clinical and reference laboratories. Its products are distributed through a dedicated direct sales force, complemented by a broad network of independent distributors and strategic partnerships.

Market cap$5.6M
Employees380
TRINITY BIOTECH PLC competitors & alternatives →
NOVACYT S.A. EUR1/15TH (CDI)NCYT · BiotechLe Vésinet, France
65% matchPublic

Novacyt S.A., together with its associated entities, specializes in the research, production, contract design, and market launch of diagnostic solutions. These offerings are primarily developed for the detection of cancer and a range of infectious diseases. The company maintains an extensive international operational footprint, encompassing the United Kingdom, the broader European continent, the United States, the Asia Pacific region, the Middle East, and Africa. Its operations are segmented into three core divisions: Primer Design, Lab21 Products, and IT-IS International. The Primer Design segment is dedicated to the conceptualization, manufacturing, and commercialization of molecular real-time qPCR testing equipment and corresponding reagents, specifically for infectious disease diagnostics. The Lab21 Products division focuses on the development, production, and supply of various protein-based in-vitro diagnostic (IVD) devices that target infectious illnesses. Meanwhile, IT-IS International is responsible for engineering and fabricating PCR devices utilized within both the life sciences and food testing industries. Novacyt serves a diverse client base, including healthcare institutions and corporate organizations. The company was established in 2006 and is headquartered in Vélizy-Villacoublay, France.

Market cap$45.2M
Employees234
NOVACYT S.A. EUR1/15TH (CDI) competitors & alternatives →

Get DIASORIN's news by email

Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.

Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →

Share this card

Post the link and the card appears automatically — each network fetches the image itself.

DIASORIN — share card preview

Instagram, TikTok and Slack canvases don't expand links — download the card as a PNG and post it as an image instead.

More on DIASORIN in Xcout Intel

  • 2 named people with titles, LinkedIn and board committees
  • The full competitor set, tracking, exports and API access
Subscribe to Xcout Intel →